Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic PatientsA Report From the National Heart, Lung, and Blood Institute Dynamic Registry
Suresh R. Mulukutla, MD*,*,
Helen A. Vlachos, MSc*,
Oscar C. Marroquin, MD*,
Faith Selzer, PhD*,
Elizabeth M. Holper, MD ,
J. Dawn Abbott, MD ,
Warren K. Laskey, MD ,
David O. Williams, MD,
Conrad Smith, MD*,
William D. Anderson, MD*,
Joon S. Lee, MD*,
Vankeepuram Srinivas, MD||,
Sheryl F. Kelsey, PhD*,
Kevin E. Kip, PhD¶
* University of Pittsburgh, Pittsburgh, Pennsylvania
University of Texas-Southwestern, Dallas, Texas
Rhode Island Hospital, Providence, Rhode Island
University of New Mexico, Albuquerque, New Mexico
|| Montefiore Medical Center, New York, New York
¶ University of South Florida, Tampa, Florida.
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Repeat Revascularization Event Rates
Kaplan-Meier 1-year curves of the incidence of the composite endpoint of post-discharge repeat percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) by diabetes treatment regimen and use of drug-eluting stent (DES) versus bare-metal stent (BMS).
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Death or Myocardial Infarction Event Rates
Kaplan-Meier 1-year curves of the incidence of the composite end point of death or myocardial infarction (MI) by diabetes treatment regimen and use of DES versus BMS. Abbreviations as in Figure 1.
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Relative Benefit of DES Over BMS for Safety and Efficacy
Adjusted hazard ratios (solid squares) and 95% confidence intervals (horizontal lines) for safety and efficacy outcomes at 1-year comparing DES-treated versus BMS-treated (referent category) patients, stratified by diabetes treatment regimen. Variables adjusted for included age, vessel disease, history of congestive heart failure, hypertension, prior coronary intervention, peripheral vascular disease, history of hypercholesterolemia, number of significant lesions, renal disease, presence of total occlusion, tortuous lesion, unstable angina, acute myocardial infarction, cardiogenic shock, emergency procedure, urgent procedure, attempted an ostial lesion, attempted a class C lesion, attempted lesion receiving collaterals, attempted thrombus, and discharge medication (i.e., presence of at least 2 of the following: beta-blockers, calcium blocker, long-acting nitrates, angiotensin-converting enzyme inhibitors, statins, clopidogrel/ticlopidine). Abbreviations as in Figure 1.
|
|
|
